HCP Live Staff

Articles

The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

May 10th 2023

Dermatologists Raj Chovatiya, MD, PhD, and David Rosmarin, MD, discuss new research outcomes for the topical JAK inhibitor live from the Revolutionizing Atopic Dermatiti 2023 Annual Meeting in Washington, DC.

Managing Vitiligo in 2023: New Therapies, Emerging Data, Pediatric Indications

HCP Live Staff

May 10th 2023

Institutional Perspectives: Cardiovascular Risk Management, Chaired By Manesh Patel, MD

HCP Live Staff

July 28th 2021

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.

IPG: Inflammatory Bowel Disease Chaired by Bruce Sands, MD

HCP Live Staff

July 12th 2021

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

Once-weekly Albiglutide Injection for Type 2 Diabetes Approved by FDA

HCP Live Staff

April 15th 2014

The US Food and Drug Administration has approved Tanzeum (albiglutide), a once-weekly subcutaneous injection for the treatment of type 2 diabetes in adults.